- Realizing the promise of this unprecedented era of medical innovation
- Meeting the challenges of new modalities across process, analytical, quality, regulatory and digital
- Adapting to emerging technologies and managing risks while improving productivity and speed-to-market
- Fostering active industry partnerships, including with CMOs and regulators, to ensure transformative patient benefit
Sanat Chattopadhyay
Executive Vice President, President Merck Manufacturing Division
Merck
Sanat Chattopadhyay is responsible for the company’s (approx. $64 billion revenue) worldwide manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines, biologics and animal health products. Merck is known as MSD outside of the U.S. and Canada.
Sanat joined Merck in 2009 as Senior Vice President of Global Vaccines & Sterile Manufacturing Operations, spearheading the transformation of manufacturing and supply chain to grow and globalize its Vaccine business. Under Sanat’s leadership, Merck is currently executing a significant expansion of its biologics and vaccines manufacturing capacity with planned capital investments of more than $20 billion from 2020 through the end of 2024, to reach more patients around the globe.
Before joining Merck, he served as Senior Vice President, Technical Operations & Product Supply, for Wyeth Pharmaceuticals. Previously, he worked at Aventis and its predecessor companies as Senior Vice President, Industrial Operations, having served in many positions with increasing responsibilities for global supply chain, technology and manufacturing sites across North America, Europe and Asia Pacific. Sanat started his career with Hoechst Pharmaceuticals in 1983 and worked in many senior leadership assignments.
Sanat is a graduate in Chemical Engineering and holds a post-graduate degree in Industrial Engineering from India.
Outside of Merck, Sanat is a member of the Board of Directors of Ashland Inc.
